Publications
Detailed Information
Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: A retrospective matched case-control study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Kyoung-Ho | - |
dc.contributor.author | Jeon, Jae Hyun | - |
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Park, Sang-Won | - |
dc.contributor.author | Oh, Myoung-don | - |
dc.contributor.author | Kim, Nam Joong | - |
dc.contributor.author | Choe, Kang Won | - |
dc.contributor.author | Lee, Hyo-Suk | - |
dc.contributor.author | Kim, Hong Bin | - |
dc.date.accessioned | 2012-06-22T07:49:04Z | - |
dc.date.available | 2012-06-22T07:49:04Z | - |
dc.date.issued | 2009-04-12 | - |
dc.identifier.citation | BMC INFECTIOUS DISEASES; Vol.9 ;41 | ko_KR |
dc.identifier.issn | 1471-2334 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77335 | - |
dc.description.abstract | Background: Clinical outcomes of spontaneous bacterial peritonitis (SBP) due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species (ESBL-EK) have not been adequately investigated. Methods: We conducted a retrospective matched case-control study to evaluate the outcomes of SBP due to ESBL-EK compared with those due to non-ESBL-EK. Cases were defined as patients with liver cirrhosis and SBP due to ESBL-EK isolated from ascites. Control patients with liver cirrhosis and SBP due to non-ESBL-EK were matched in a 3: 1 ratio to cases according to the following five variables: age (+/- 5 years); gender; species of infecting organism; Child-Pugh score (+/- 2); Acute Physiological and Chronic Health Evaluation II score (+/- 2). `Effective initial therapy` was defined as less than 72 hours elapsing between the time of obtaining a sample for culture and the start of treatment with an antimicrobial agent to which the EK was susceptible. Cephalosporin use for ESBL-EK was considered `ineffective`, irrespective of the minimum inhibitory concentration. ESBL production was determined according to the Clinical and Laboratory Standards Institute guidelines on stored isolates. Results: Of 1026 episodes of SBP in 958 patients from Jan 2000 through Dec 2006, 368 (35.9%) episodes in 346 patients were caused by SBP due to EK, isolated from ascites. Of these 346 patients, twenty-six (7.5%) patients with SBP due to ESBL-EK were compared with 78 matched controls. Treatment failure, evaluated at 72 hours after initial antimicrobial therapy, was greater among the cases (15/26, 58% vs. 10/78, 13%, P = .006); 30-day mortality rate was also higher than in the controls (12/26, 46% vs. 11/78, 15%, P = .001). When the case were classified according to the effectiveness of the initial therapy, `ineffective initial therapy` was associated with higher 30-day mortality rate (11/18, 61% vs. 1/8, 13%, P = .036). Conclusion: SBP due to ESBL-EK had poorer outcomes than SBP due to non-ESBL-EK. Ineffective initial therapy seems to be responsible for the higher rate of treatment failure and mortality in SBP due to ESBL-EK. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BIOMED CENTRAL LTD | ko_KR |
dc.title | Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: A retrospective matched case-control study | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 송경호 | - |
dc.contributor.AlternativeAuthor | 전재현 | - |
dc.contributor.AlternativeAuthor | 박완범 | - |
dc.contributor.AlternativeAuthor | 박상원 | - |
dc.contributor.AlternativeAuthor | 김홍빈 | - |
dc.contributor.AlternativeAuthor | 오명돈 | - |
dc.contributor.AlternativeAuthor | 이효석 | - |
dc.contributor.AlternativeAuthor | 김남중 | - |
dc.contributor.AlternativeAuthor | 최강원 | - |
dc.identifier.doi | 10.1186/1471-2334-9-41 | - |
dc.citation.journaltitle | BMC INFECTIOUS DISEASES | - |
dc.description.citedreference | Christou L, 2007, AM J GASTROENTEROL, V102, P1510, DOI 10.1111/j.1572-0241.2007.01286.x | - |
dc.description.citedreference | Cho JH, 2007, SCAND J INFECT DIS, V39, P697, DOI 10.1080/00365540701299582 | - |
dc.description.citedreference | Hyle EP, 2005, ARCH INTERN MED, V165, P1375 | - |
dc.description.citedreference | Jacoby GA, 2005, NEW ENGL J MED, V352, P380, DOI 10.1056/NEJMra041359 | - |
dc.description.citedreference | Kang CI, 2004, INFECT CONT HOSP EP, V25, P860 | - |
dc.description.citedreference | Paterson DL, 2004, CLIN INFECT DIS, V39, P31 | - |
dc.description.citedreference | Paterson DL, 2004, ANN INTERN MED, V140, P26 | - |
dc.description.citedreference | KANG CI, 2004, KOREAN J INTERN MED, V19, P160 | - |
dc.description.citedreference | Cosgrove SE, 2003, CLIN INFECT DIS, V36, P1433 | - |
dc.description.citedreference | Paterson DL, 2003, CLIN INFECT DIS, V36, P1006 | - |
dc.description.citedreference | Kim BN, 2002, J HOSP INFECT, V52, P99, DOI 10.1053/jhin.2002.1288 | - |
dc.description.citedreference | Kim YK, 2002, ANTIMICROB AGENTS CH, V46, P1481, DOI 10.1128/AAC.46.5.1481-1491.2002 | - |
dc.description.citedreference | Franca AVC, 2002, J GASTROENTEROL, V37, P119 | - |
dc.description.citedreference | Fernandez J, 2002, HEPATOLOGY, V35, P140, DOI 10.1053/jhep.2002.30082 | - |
dc.description.citedreference | Lautenbach E, 2001, CLIN INFECT DIS, V32, P1162 | - |
dc.description.citedreference | Rimola A, 2000, J HEPATOL, V32, P142 | - |
dc.description.citedreference | Schiappa DA, 1996, J INFECT DIS, V174, P529 | - |
dc.description.citedreference | RIMOLA A, 1995, DIAGN MICR INFEC DIS, V22, P141 | - |
dc.description.citedreference | RIMOLA A, 1995, HEPATOLOGY, V21, P674 | - |
dc.description.citedreference | INFANTERIVARD C, 1987, HEPATOLOGY, V7, P660 | - |
dc.description.citedreference | KNAUS WA, 1985, CRIT CARE MED, V13, P818 | - |
dc.description.citedreference | HOEFS JC, 1985, DM-DIS MON, V31, P1 | - |
dc.description.citedreference | FELISART J, 1985, HEPATOLOGY, V5, P457 | - |
dc.description.tc | 14 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.